Financial Contrast: Beyond Air (NASDAQ:XAIR) & Valeritas (OTCMKTS:VLRXQ)

Valeritas (OTCMKTS:VLRXQ) and Beyond Air (NASDAQ:XAIR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Valeritas and Beyond Air, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valeritas	0	0	0	0	0.00
Beyond Air	0	1	3	1	3.00

Beyond Air has a consensus target price of $3.67, indicating a potential upside of 1,267.14%. Given Beyond Air’s stronger consensus rating and higher probable upside, analysts clearly believe Beyond Air is more favorable than Valeritas.

Profitability

This table compares Valeritas and Beyond Air’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valeritas	N/A	N/A	N/A
Beyond Air	-1,730.00%	-226.01%	-109.75%

Insider and Institutional Ownership

31.5% of Beyond Air shares are held by institutional investors. 1.0% of Valeritas shares are held by insiders. Comparatively, 20.1% of Beyond Air shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Valeritas and Beyond Air”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valeritas	N/A	N/A	N/A	N/A	N/A
Beyond Air	$3.02 million	6.10	-$60.24 million	($1.06)	-0.25

Valeritas has higher earnings, but lower revenue than Beyond Air.

Summary

Beyond Air beats Valeritas on 7 of the 10 factors compared between the two stocks.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.